Results 301 to 310 of about 114,155 (318)

Review Article: Novel Enzyme Therapy Design for Gluten Peptide Digestion Through Exopeptidase Supplementation

Alimentary Pharmacology &Therapeutics, Volume 61, Issue 7, Page 1123-1139, April 2025.
Exopeptidases are key for completing protein digestion, including proline‐rich peptides, and are mostly produced by enterocytes of the intestinal brush border membrane. In coeliac disease, chronic inflammation leads to reduced brush border exopeptidase activity, exacerbating peptide accumulation.
Erin R. Bonner, Werner Tschollar, Robert Anderson, Sulayman Mourabit   +3 more
wiley   +1 more source

Low-grade duodenal neuroendocrine tumor in a 72-year-old man: A case report. [PDF]

Int J Surg Case Rep
Al-Jawad M, Hashemagha D, Salem A, Seijari N, Hussein S, Niazi A.   +5 more
europepmc   +1 more source

Functional Dyspepsia and Its Subgroups: Prevalence and Impact in the Rome IV Global Epidemiology Study

Alimentary Pharmacology &Therapeutics, EarlyView.
Prevalence of functional dyspepsia in the general population in each country of the internet survey of the Rome IV global epidemiology study. ABSTRACT Background Functional dyspepsia (FD) is one of the most common disorders of gut–brain interaction (DGBI). Varying reported population prevalences probably reflect different definitions and methodological
J. Tack, O. S. Palsson, S. I. Bangdiwala, J. Schol, F. Carbone, K. Van Den Houte, B. Broeders, D. Drossman, D. L. Dumitrascu, X. Fang, S. Fukudo, U. C. Ghoshal, J. Kellow, R. Khatun, E. Okeke, E. M. Quigley, M. Schmulson, M. Simrén, W. E. Whitehead, P. Whorwell, A. D. Sperber   +20 more
wiley   +1 more source

The Duodenal Microenvironment in Functional Dyspepsia. [PDF]

J Neurogastroenterol Motil
Huyghe P, Ceulemans M, Keita ÅV, Söderholm J, Depoortere I, Tack J, Wauters L, Vanuytsel T.   +7 more
europepmc   +1 more source

How I treat iron‐refractory iron deficiency anaemia—An expert opinion‐based treatment guidance for children and adults

British Journal of Haematology, Volume 206, Issue 4, Page 1067-1076, April 2025.
In iron‐refractory iron deficiency anaemia, inappropriately elevated hepcidin levels impair enteral iron absorption and iron release from macrophages by interacting with ferroportin. Oral iron supplements (containing ~30 mg Fe2+ per 100 mg) are generally ineffective due to this hepcidin–ferroportin interaction although, in some cases, this can be ...
V. Hoving, A. E. Donker, S. E. M. Schols, D. W. Swinkels   +3 more
wiley   +1 more source

Triple Bypass for Chronic Pancreatitis With Biliary and Duodenal Stenosis: A Report of Two Cases. [PDF]

Cureus
Noguchi A, Ishida M, Douchi D, Mizuma M, Unno M.   +4 more
europepmc   +1 more source

Iron trapping in macrophages reshapes the homeostasis of the haematopoietic system

British Journal of Haematology, Volume 206, Issue 5, Page 1485-1496, May 2025.
Deletion of ferroportin (Fpn) in myeloid cells results in iron trapping in macrophages and reshapes whole haematopoiesis with ageing. Impaired local iron supply to bone marrow (BM) leads to anaemia and microcytaemia, unbalanced megakaryopoiesis versus erythropoiesis and reduced BM cells starting from haematopoietic stem cells.
Laura Crisafulli, Margherita Correnti, Elena Gammella, Elisa De Camilli, Matteo Brindisi, Eleonora Palagano, Chiara Milanesi, Gabriele Todisco, Matteo G. Della Porta, Cristina Sobacchi, Gaetano Cairo, Francesca Ficara, Stefania Recalcati   +12 more
wiley   +1 more source

Percutaneous transhepatic cholangioscopy with cholangiography-guided choledochojejunostomy: a bridge drainage technique for distal common bile duct stenosis after Beger's operation. [PDF]

Endoscopy
Chen R, Zhang J, Chen T, Zhang J, Zhou R.   +4 more
europepmc   +1 more source

Treating Hematological Malignancies With OR‐2100, an Orally Bioavailable Prodrug of Decitabine

Cancer Science, Volume 116, Issue 4, Page 853-861, April 2025.
We have developed a silylated derivative of decitabine, OR‐2100, which is resistant to degradation by cytidine deaminase and orally bioavailable. In this article, we review the current status of DNA demethylating agents for treating hematological malignancies, with a focus on OR‐2100. ABSTRACT DNA methylation is an enzyme‐driven epigenetic modification
Tatsuro Watanabe, Keisuke Kidoguchi, Shinya Kimura   +2 more
wiley   +1 more source